GW Pharmaceuticals, the maker of Sativex, a medical spray derived from cannabis, has appointed Stephen Schultz to the new role of US-based vice president of investor relations.
The London-listed firm, which was the first in the world to receive approval for a cannabis-based medicine, has also filed to list American depositary receipts on the NASDAQ Global Market.
‘GW Pharmaceuticals represents a compelling investment story,’ says Schultz. ‘Sativex is a unique and exciting product which is now the subject of a substantial Phase 3 program in the US.’
He adds: ‘Beyond Sativex lies a highly promising pipeline of cannabinoid drug candidates in development. I look forward to working with the GW team as the company capitalizes on such significant market opportunities.’
Justin Gover, GW’s managing director, also sees big potential in the US market. ‘With our lead product, Sativex, now advancing through Phase 3 clinical trials for cancer pain in the US, the US is taking an ever increasing prominence in the GW story,’ says Gover.
‘Steve’s investor relations expertise in the US will allow GW to increase significantly our exposure to a substantially larger investment base and analyst community.’
Schultz brings over two decades of experience in investor relations, financial communications and media relations to the role. He previously served as senior director of IR and corporate communications at another biopharmaceutical company, the NASDAQ-listed Amarin Corporation.
Prior to Amarin, Schultz was executive director at the Jackson Hole Center for the Arts, a not-for-profit arts organization, and also held positions at Acusphere, Shareholder.com, Manufacturer’s Services Limited, Wang Global and The Forefront Group.
